Open AccessApoptotic Action of 17 -Estradiol in Raloxifene-Resistant MCF-7 Cells In Vitro and In Vivo
Author(s) -
H. Liu
Publication year - 2003
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djg080
Subject(s) - raloxifene , selective estrogen receptor modulator , tamoxifen , mcf 7 , endocrinology , antiestrogen , medicine , apoptosis , estrogen , cancer research , estrogen receptor , cell cycle , cell growth , breast cancer , biology , cancer , biochemistry , human breast
Resistance to tamoxifen, a selective estrogen receptor modulator (SERM), involves changes that prevent apoptosis and enhance cell proliferation and survival. Paradoxically, estrogen treatment inhibits the growth of long-term tamoxifen-treated breast tumors. Because of the increasing use of raloxifene, another SERM, to prevent osteoporosis and potentially reduce breast cancer risk, some women will develop raloxifene-resistant breast cancer. We developed a raloxifene-resistant MCF-7 cell model (MCF-7/Ral) and investigated the nature of raloxifene-resistant breast cancer and its response to estradiol.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom